Skip to main content
PLOS One logoLink to PLOS One
. 2021 Apr 29;16(4):e0250505. doi: 10.1371/journal.pone.0250505

An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox’s Bazar, Bangladesh: Findings from enhanced epidemiological surveillance

Md Khadimul Anam Mazhar 1,*, Flavio Finger 2,3,4, Egmond Samir Evers 1, Anna Kuehne 2,5,6,7, Melissa Ivey 8, Francis Yesurajan 1, Tahmina Shirin 9, Nurul Ajim 8, Ahammadul Kabir 1, Jennie Musto 1, Kate White 8, Amrish Baidjoe 1,2,6,10, Olivier le Polain de Waroux 2,5,6,7
Editor: Hans Tillmann11
PMCID: PMC8084213  PMID: 33914782

Abstract

In the summer of 2017, an estimated 745,000 Rohingya fled to Bangladesh in what has been described as one of the largest and fastest growing refugee crises in the world. Among numerous health concerns, an outbreak of acute jaundice syndrome (AJS) was detected by the disease surveillance system in early 2018 among the refugee population. This paper describes the investigation into the increase in AJS cases, the process and results of the investigation, which were strongly suggestive of a large outbreak due to hepatitis A virus (HAV). An enhanced serological investigation was conducted between 28 February to 26 March 2018 to determine the etiologies and risk factors associated with the outbreak. A total of 275 samples were collected from 18 health facilities reporting AJS cases. Blood samples were collected from all patients fulfilling the study specific case definition and inclusion criteria, and tested for antibody responses using enzyme-linked immunosorbent assay (ELISA). Out of the 275 samples, 206 were positive for one of the agents tested. The laboratory results confirmed multiple etiologies including 154 (56%) samples tested positive for hepatitis A, 1 (0.4%) positive for hepatitis E, 36 (13%) positive for hepatitis B, 25 (9%) positive for hepatitis C, and 14 (5%) positive for leptospirosis. Among all specimens tested 24 (9%) showed evidence of co-infections with multiple etiologies. Hepatitis A and E are commonly found in refugee camps and have similar clinical presentations. In the absence of robust testing capacity when the epidemic was identified through syndromic reporting, a particular concern was that of a hepatitis E outbreak, for which immunity tends to be limited, and which may be particularly severe among pregnant women. This report highlights the challenges of identifying causative agents in such settings and the resources required to do so. Results from the month-long enhanced investigation did not point out widespread hepatitis E virus (HEV) transmission, but instead strongly suggested a large-scale hepatitis A outbreak of milder consequences, and highlighted a number of other concomitant causes of AJS (acute hepatitis B, hepatitis C, Leptospirosis), albeit most likely at sporadic level. Results strengthen the need for further water and sanitation interventions and are a stark reminder of the risk of other epidemics transmitted through similar routes in such settings, particularly dysentery and cholera. It also highlights the need to ensure clinical management capacity for potentially chronic conditions in this vulnerable population.

Introduction

Since August 2017, an estimated 745,000 Rohingya—including more than 400,000 children below 18 years—have fled to Cox’s Bazar district, Bangladesh from Rakhine state in Myanmar [1]. Pre-existing settlements, from earlier influxes rapidly expanded into large and dense mega-settlements. Today, an estimated total of 860,000 [2] stateless refugees live in 34 densely populated camps in Cox’s Bazar district, in what has been described as one of the largest and fastest growing refugee crises in the world [3]. The rapid settlement of this vulnerable population into overcrowded camps, with inadequate provision of water, sanitation, or general hygiene standards, combined with the high population density are some of the factors that led to an increased risk of infectious disease outbreaks, compounded by vulnerability factors such as nutritional deficiencies and low pre-existing routine vaccination coverage [4].

An Early Warning, Alert and Response (EWAR) system was put in place by the World Health Organization (WHO) and the Bangladesh Ministry of Health and Family Welfare (MoHFW) in collaboration with multiple partners across the camps to help monitor and rapidly detect potential infectious diseases threats [5,6]. This allowed health facilities to report weekly case counts of different conditions/syndromes for which set thresholds were established which, when triggered, required investigation within 48 hours. In addition, EWAR health facilities immediately report unusual events of potential severity or any potential case or cluster requiring immediate investigation after initial verification of the event.

Acute Jaundice Syndrome (AJS) is not uncommon in refugee settings and can be caused by various infectious etiologies, such as acute viral hepatitis E, A, B, C, or more rarely leptospirosis, as well as non-infectious liver disease. The main differential diagnoses for these diseases and their transmission routes are summarised in S1 Appendix. Given the high population density and poor sanitation conditions usually found in such settings, hepatitis A and E can easily spread within a susceptible population. Of particular concern is Hepatitis E which can cause severe outcomes in pregnant women, with case fatality ratios (CFR) up to 10% reported in recent outbreaks [79] and which has been the leading cause of acute hepatitis in pregnancy in Myanmar [10]. In addition, Hepatitis E is less endemic, meaning that a lower proportion of adults tend to be immune, compared to hepatitis A, which classically affects mostly younger age groups in highly-endemic settings [79].

The prevalence of chronic hepatitis (B and C), vary among refugee populations [11]. The country of origin of patients has shown to be an important factor and Myanmar has a high reported incidence of acute and chronic liver disease, mostly caused by Hepatitis B virus (HBV) and Hepatitis C virus (HCV) [10,12]. The incidence of leptospirosis is not well documented in Bangladesh due to lack of diagnostic tests, though it has been reported in the region and the environmental factors are present to spread the infection [13]. Similarly, the incidence of leptospirosis in Myanmar has not been studied to date.

In January 2018, alerts for Acute Jaundice Syndrome (AJS) were triggered by the surveillance system due to a rapid increase in the reported weekly incidence (initially defined as twice the average of the last three weeks reported number of cases, from each facility). Between January and April 2018, a total of 1976 cases were reported through the system, with a weekly number of 77–147 cases (average 116 per week). The number of reporting health facilities remained stable (between 110–120 per week) throughout that period, and increased to 140 by the end of the year after reported case counts tailed off (Fig 1).

Fig 1. Epidemiology curve of reported AJS cases against number of facilities reporting (monthly average) in EWAR system; and timing of changes to the surveillance system from daily to weekly.

Fig 1

Following the alerts triggered by the surveillance system, and with over 1300 reported cases and 6 deaths since late 2017, a rapid field investigation was undertaken between 5-8th February 2018. Findings from these suggested multiple etiologies with initial laboratory results from 27 patient samples collected showing 37% (10/27) positive for HAV IgM, 7% (2/27) positive for HCV, 4% (1/27) positive for HEV, and the remaining 52% (14/27) negative for all Hepatitis markers and Leptospirosis IgM. The presence of multiple etiologies found in this initial investigation, especially HAV and HEV, prompted the simultaneous establishment of an enhanced surveillance strategy to ensure detailed information about each case could be gathered and analysed, combined with and exhaustive laboratory outbreak investigation to better understand the etiologies. Here, we describe the process and findings from this enhanced surveillance and outbreak investigation.

Methods

Establishment of enhanced surveillance

An enhanced surveillance for AJS including daily reporting of cases was implemented since the beginning of 2018 in Cox’s Bazar, with the objective to identify more detailed epidemiological characteristics of reported cases. A digital case report form was developed and available on the EWAR system [6]. The form included information on detailed demographic characteristics, geographical origin of patients, clinical presentation, exposure factors (water and sanitation exposure, household environment) and laboratory results for any samples that were taken (S2 Appendix).

Exhaustive laboratory outbreak investigation

A serological investigation was conducted for approximately one month between 28 February and 26 March 2018 based on exhaustive testing of all patients presenting at a subset of 18 healthcare facilities in the camps. The main purpose of testing was to better document the etiologies at play, assuming likely co-circulation of HAV and HEV as the main causative agents, and other acute (or flare ups of chronic) HBV and HCV, potential cases of leptospirosis as well as acute hepatitis from non-infectious causes. The duration (four weeks) of the enhanced laboratory investigation was based on an opportunistic sampling exercise which was required to provide enough understanding of the key drivers of infection, based on a distribution of etiologies in an initial sample of 27 patients (collected between 5-8th February 2018), as well as pragmatic considerations of stock availability, transport, storage and sample collection and testing capacity.

Participating health facilities were proposed as those who reported >10 cases of AJS between January and February 2018 (week 1–8) in EWAR, and who self-identified as having the capacity to collect and transport samples.

Any person with acute onset of jaundice- with or without fever and absence of any known precipitating factors (EWARS Bangladesh Case Definition for Acute Jaundice Syndrome, see S3 Appendix) fulfilling the below criteria was invited to provide a blood sample:

  1. presenting at one of the 18 participating facilities (Fig 2).

  2. with a completed Case Report Form (CRF), including demographic details, clinical details, family history, patient outcome

  3. Having provided consent to having a sample taken and other information collected.

Fig 2. Map of AJS attack rate (per 10,000 population) reported through enhanced epidemiological surveillance strategy between 28 February and 26 March 2018 in the Rohingya refugee camps and locations of reporting health facilities in Cox’s Bazar, Bangladesh © 2021 by Md Khadimul Anam Mazhar is licensed under CC BY 4.0.

Fig 2

Participants were provided with information about the reason for the blood tests, and how their information would be handled and stored. Verbal consent was obtained by the medical team in charge at each of the 18 participating facilities. Participants who refused to provide consent, were excluded from sample collection.

Laboratory procedures

Samples (venous blood) were collected in a pro-coagulation (red-top) tube and stored vertically maintaining a cold chain at 2–8°C (for coagulation) before serum separation. Samples were labeled with unique IDs and transferred to a central facility (Médecins sans Frontières Kutupalong Clinic) for serum separation. Samples were later transported to the laboratory at the Institute of Epidemiology Disease Control and Research (IEDCR) in Dhaka for etiological analyses.

All samples were tested for HAV, HBV, HCV, HEV and leptospirosis using the diagnostic tests indicated in Table 1. Hepatitis testing was done using ELISA and Leptospira-IgM was tested using rapid immunochromatographic test (ICT).

Table 1. Testing algorithm.

No Disease/Pathogen Diagnostic test to be performed
1 Hepatitis A Virus HAV ELISA for IgM
2 Hepatitis B Virus Hepatitis B surface antigen
3 Hepatitis C Virus Anti-HCV antibodies
4 Hepatitis E Virus Anti-HEV ELISA for IgM
5 Leptospirosis Leptospira lateral flow for IgM

Statistical analyses

Descriptive analyses were conducted for all reported AJS cases followed by a post-hoc nested case control (case-case) analysis within the cohort of patients tested during the enhanced surveillance phase, to identify specific factors associated with hepatitis A, which was identified as the main cause for the AJS epidemic. In the analysis “Case” was classified as having Positive Hep A IgM result (HAV +ve cases) and “Control” was classified as having Negative Hep A IgM result (HAV -ve cases). Controls are not from the general population but from same cohort who presented with AJS symptoms and tested negative for Hepatitis A marker, irrespective of test results for other etiologies (Hepatitis B, C, E and Leptospirosis). Analysis was conducted to determine risk factors associated with predicted outcome (disease development) and effects of other independent variables (gender, age, age-groups, reported household transmission etc.) by measuring odds ratio with 95% confidence interval. All analysis was conducted using Stata 16.

Environmental investigation

No specific investigation was undertaken during the enhanced surveillance phase for AJS, however findings from a large water quality surveillance exercise conducted shortly before the increased incidence of AJS alerts (18 September-14 November 2017) identified significant contamination at water sources and household levels, underlining the presence of conditions for spread of water-borne disease (S4 Appendix).

Ethical consideration

The data reported were collected as part of routine public health outbreak response activities. For this publication, no additional primary data collection took place other than the data required for outbreak response and surveillance. Therefore, no additional ethical approval was sought at the time of data collection. The formulation of this work was presented and discussed with the Civil Surgeon Cox’s Bazar from the Ministry of Health & Family Welfare (MoHFW) responsible for overseeing the Rohingya refugee crisis. All individual case data was anonymized.

Results

A total of 575 AJS cases were reported through weekly reporting with a weekly average of 115 cases ranging from 88 to 158 cases from 28 February to 26 March 2018 between week 8 to week 12 in 2018. Of these reported cases, 275 were reported in the enhanced surveillance system from whom blood samples were collected. Of these, 57% (156) were male and 68% (186) were children (below <18 years) (Table 2).

Table 2. Gender and age-group distribution of reported AJS cases.

Age Group of Reported Cases Male Female Total
0 to 4 years 45 (16%) 22 (8%) 67 (24%)
5 to 9 Years 34 (12%) 25 (9%) 59 (21%)
10 to 17 Years 34 (12.3%) 26 (9.4%) 60 (21.7%)
18 years or more 43 (15.6%) 46 (16.7%) 89 (32.3%)
Total 156 (56.7%) 119 (43.3%) 275 (100%)

Camp-wise weekly attack rate (AR) per 10,000 population was calculated for the reported 275 AJS cases detected by the enhanced epidemiological surveillance strategy between 28 February and 26 March 2018. The weekly mean attack rate over the enhanced surveillance period (28 February to 26 March 2018) was 0.60 (95% CI: 0.28 to 0.92) per 10,000 population, across all the camps for the reported AJS cases. However, the AR varies among age-groups and was higher in younger age-groups (see Table 3). AR (per 10,000 population) for different age-groups is graphically presented in S5 Appendix.

Table 3. Attack rate of reported AJS cases by age-group* and gender among all 34 camps between 28 February and 26 March 2018 in Cox’s Bazar, Bangladesh.

Weekly AR/10,000 population (95% CI)
Overall 0.60 (0.28 to 0.92)
By age-group
0–4 years 0.80 (0.34 to 1.26)
5–11 years 0.73 (0.36 to 1.10)
12–17 years 0.71 (0.31 to 1.11)
18+ years 0.43 (0.15 to 0.92)
By gender
Female 0.49 (0.21 to 0.77)
Male 0.71 (0.33 to 1.09)

* Population data from UNHCR Bangladesh Operational Update, 1–15 August 2018, was used to calculate the AJS attack rate [14].

All AJS cases presented with jaundice, as per reporting definition, combined with other symptoms. In total 67% (183/275) presented with fever, 56% (155/275) with nausea, 41% (113/275) with abdominal pain, 25% (70/275) with vomiting, 21% (57/275) with fatigue, 14% (38/275) with itching, 13% (37/275) with joint pain, 9% (27/275) with loss of appetite, 9% (26/275) with dark urine, 3% (7/275) with bleeding and 2% (6/275) with convulsion (Fig 3).

Fig 3. Presenting symptoms of reported AJS cases.

Fig 3

Out of the 275 samples, 206 were positive for at least one of the agents tested. The laboratory results confirmed multiple etiologies including 154 (56%) samples tested positive for Hepatitis A, 1 (0.4%) positive for Hepatitis E, 36 (13%) positive for Hepatitis B, 25 (9%) positive for Hepatitis C, and 14 (5%) positive for Leptospirosis.

Among all specimens tested 24 (9%) showed evidence of co-infections with multiple etiologies. Of these, 4% (11/275) had HAV-HBV co-infection, 0.7% (2/275) had HAV-HCV co-infection, 0.4% (1/275) had HAV-HEV co-infection, 0.4% (1/275) had HAV-LEPT co-infection; 0.7% (2/275) had HBV-HCV co-infection, 0.4% (1/275) had HBV-LEPT co-infection and 0.4% (1/275) had HCV-LEPT co-infection. The remaining 69 (25%) samples tested negative for all tests.

Descriptive age-group analysis showed that among all Hepatitis A positives cases (154), 38% (58/154) were aged 0–4 years, 34% (3252/154) were aged 5–9 years, 21% (32/154) were aged 10–17 years and the remaining 8% (12/154) were adults (18 years or above). The only case found to be positive for Hepatitis E was aged 5–9 years. Half (18/36) of the Hepatitis B positives case were reported among younger age-groups (<18 years), whereas for HCV only 8% (2/25) were reported in younger age-groups (<18 years). Among all (14) leptospirosis cases there were male predominance (64%) and all cases were in older children (29% in 10 to 17 years) and in adult (71% in 18 years or above) age groups (Fig 4).

Fig 4. Age and sex distribution of AJS cases with their seropositivity collected during exhaustive sampling, 28 February– 26 March 2018, Cox’s Bazar, Bangladesh.

Fig 4

(A) Hepatitis A seropositivity. (B) Hepatitis B seropositivity. (C) Hepatitis C seropositivity. (D) Leptospirosis seropositivity.

Among all AJS cases, 8% (23/ 275) reported household exposure, of which 13 (56%) were female and 10 (44%) were male which represents 11% (13/113) of all reported female and 6.4% (10/156) all reported male AJS cases. Of these 23 cases reported with household exposure, only 11 females and 5 males tested positive for Hepatitis A.

Additional analyses were performed to examine the association between hepatitis A seropositivity with age, gender and other risk factors. Univariate regression analysis showed that the odds of developing hepatitis A was lower in older age groups (10–17 and 18+ years) compared to younger age-group (0–4 years) with a p-value of <0.001. (Table 4). Univariate analysis also showed no association between hepatitis A seropositivity and gender (p-value 0.256) (Table 4).

Table 4. Association of hepatitis A seropositivity with age-group, gender, presenting symptoms and drinking water sources.

OR (95% CI) P-value
Age-group
0–4 years (n = 67) 1.0* -
5–9 years (n = 59) 1.15 (0.40 to 3.13) 0.79
10–17 years (n = 60) 0.18 (0.07 to 0.42) < 0.001
18+ years (n = 89) 0.02 (0.01 to 0.06) < 0.001
Gender
Female (n = 119) 1.0* -
Male (n = 156) 1.32 (0.82 to 2.14) 0.256
Presenting symptoms#
Fever (n = 183) 2.25 (1.35 to 3.76) 0.002
Nausea (n = 155) 1.19 (0.76 to 1.93) 0.479
Abdominal pain (n = 113) 0.81 (0.50 to 1.31) 0.385
Vomiting (n = 70) 1.85 (1.05 to 3.27) 0.034
Fatigue (n = 57) 0.83 (0.46 to 1.50) 0.542
Itching (n = 38) 1.23 (0.61 to 2.47) 0.563
Joint pain (n = 37) 0.42 (0.21 to 0.86) 0.018
Loss of Appetite (n = 27) 3.83 (1.40 to 10.45) 0.009
Dark Urine (n = 26) 3.63 (1.32 to 9.94) 0.012
Bleeding (n = 7) 1.04 (0.23 to 4.74) 0.960
Convulsion (n = 6) 0.38 (0.07 to 2.12) 0.271
Drinking water sources^
Tube-well (n = 170) 1.27 (0.78 to 2.06) 0.342
Tap water (n = 45) 1.22 (0.63 to 2.33) 0.555
Unknown sources (n = 58) 0.56 (0.32 to 1.01) 0.055

*Baseline category

#Diarrhoea (n = 1) and other (n = 2) symptoms were omitted from the summary table

^ water truck (n = 2) was omitted from the summary table.

We explored whether presenting symptoms among AJS cases were associated with hepatitis A seropositivity. Univariate analysis showed that HAV was positively associated with fever (OR 2.25; 95% CI: 1.35 to 3.76); dark urine (OR 3.63; 95% CI: 1.32 to 9.94); loss of appetite (OR 3.83; 95% CI: 1.40 to 10.45) and vomiting (OR 1.85; 95% CI: 1.05 to 3.27), and negatively associated with joint pain (OR 0.42; 95% CI 0.21–0.86) (Table 4). Etiological risk factor data collected from the cases indicate different sources were used for drinking water including tube wells, communal tap, water supply trucks. However, univariate regression analysis showed no association between reported drinking water source type and hepatitis A seropositivity (Table 4 and Fig 5).

Fig 5. Odds ratio for the association of hepatitis A seropositivity with age-group, gender, presenting symptoms and drinking water sources.

Fig 5

Additional nested case control (case-case study) analyses showed no association between hepatitis A seropositivity and a reported case of AJS in the household (p-value 1.77). However, sub-group analysis showed that female HAV cases were more likely to have reported household transmission (for definition see S6 Appendix) than males, with a OR of 5.93 (95% CI:1.25 to 28.1; p-value: 0.025). The univariate regression analysis among age-groups showed that, compared to younger age groups (0–4 years; 5–9 years and 10–17 years), adult HAV cases (18 years or above) were more likely to have reported household transmission with an OR of 18.75 (95% CI: 2.96 to 118.92; p-value: 0.002) (see Table 5).

Table 5. Odds ratio for the association between household transmission and hepatitis A seropositivity by gender.

AJS case in the household** OR (95% CI) P-value
Overall Hepatitis A negative (n = 121) 1.0* -
Hepatitis A positive (n = 154) 1.88 (0.75 to 4.75) 0.177
By Gender
Female Hepatitis A negative (n = 57) 1.0* -
Hepatitis A positive (n = 62) 5.93 (1.25 to 28.06) 0.025
Male Hepatitis A negative (n = 64) 1.0* -
Hepatitis A positive (n = 92) 0.68 (0.19 to 2.45) 0.553
By age-groups
0–4 years Hepatitis A negative (n = 9) 1.0* -
Hepatitis A positive (n = 58) 0.15 (0.03 to 0.83) 0.029
5–9 years Hepatitis A negative (n = 7) 1.0* -
Hepatitis A positive (n = 52) 1.0 (omitted) -
10–17 years Hepatitis A negative (n = 28) 1.0* -
Hepatitis A positive (n = 32) 0.87 (0.11 to 6.59) 0.890
18+ years Hepatitis A negative (n = 77) 1.0* -
Hepatitis A positive (n = 12) 18.75 (2.96 to 118.92) 0.002

*Baseline category

**In the 8 weeks preceding symptom onset.

Discussion

The investigation into an outbreak of acute jaundice syndrome in the Rohingya refugee camps revealed a hepatitis A epidemic and multiple other infectious etiologies contributing to AJS (acute HBV, HCV, leptospirosis). Data from enhanced epidemiological surveillance suggests that at least 154 were infected (56% of the reported AJS cases) with HAV between February and March 2018 which was the most common underlying cause of AJS among the tested cases, and driving the epidemic dynamics, followed by Hepatitis B and hepatitis C which likely contributed to background levels of AJS in the camps Hepatitis E was observed in only one of the 275 samples.

The results highlight the importance of early warning, alert and response (EWAR) system in humanitarian contexts, as well as the need for such surveillance processes to be versatile and easily adaptable to respond to new outbreaks as they arise. Here, following the identification of an AJS outbreak through EWAR, a short-term enhanced surveillance system was put in place to investigate the potential causative agents and related risk factors linked to them, in order to guide outbreak response.

Since sampling was conducted at selected sites and during a short period of time, results are likely to have been exposed to selection bias. The results nevertheless provided a good overview of the causative etiologies of AJS in the camps.

Sub-standard water and sanitation conditions and lack of hygiene practices in the camps were observed at the time of data collection as indicated by the findings from the water quality surveillance (S Appendix), coupled with crowded living conditions are fertile grounds for enteric and waterborne pathogens, including hepatitis A. Hepatitis A and E are most commonly transmitted via the fecal-oral route [15], and Consumption of contaminated food and water is the leading cause of HAV and HEV outbreaks in refugee camp settings [7]. In high incidence settings, hepatitis A infection tend to mostly affect children, due to existing immunity in older age groups, as corroborated by our results. One of the concerns at the start of the epidemic was a Hepatitis E outbreak, which may cause fetal loss and high maternal mortality, and which has often been associated with large water borne outbreaks [16]. HEV is also one of the most common causes of acute viral hepatitis in this region and is common in rural areas in Bangladesh [17,18]. While the investigation did not point towards extensive HEV circulation, presence of the virus and the similarity of transmission routes with Hepatitis A called for particular attention to be given to pregnant women, who are at high risk of complications if affected by HEV within the third trimester, and continued vigilance of any flare up of AJS in the camps in the future.

Our investigation showed that, among adults, the risk of HAV positivity was higher for individuals who reported previous AJS cases in their household, within 8 weeks, and females in particular had a higher risk. This may reflect differential risks of infection within the household setting, potentially linked to care giving roles.

While Hepatitis B and C were not drivers of the AJS epidemic, the detection of significant number of infections requires attention and likely reflects high prevalence of chronic infections. l. One small study has shown significant prevalence of HBV and HCV among the Rohingya population in Bangladesh [15] and warrants further serological investigation in particular given limited capacity for clinical management within the district. Hepatitis B vaccination is part of the routine EPI programmes in the camps, and our results highlight the need to ensure adequate coverage, as well as a zero dose to new-borns to protect from spread of the infection, with close monitoring of identified cases. There is also need to maintain routine immunization programmes, to improve vaccine coverage of Hepatitis B among women of reproductive age (WRA) and under-five children both in the camps and the surrounding host community [4]. This might, in turn, reduce the perinatal transmission of hepatitis viruses [19].

Presence of leptospirosis has been a surprising but not unexpected finding. Laboratory testing for leptospirosis is not commonly practiced in Cox’s Bazar. The camps have associated environmental factors like a temperate climate and floods due to heavy rainfalls and recreational activities including swimming are common, so these may spread the infection [20]. Environmental exposures are likely higher in male and also in older age groups and might contribute to developing the disease.

For conducting this rapid investigation in the Rohingya camps, one of the biggest challenges was to ensure a minimum standard for sample collection. At the time of the investigation, very few facilities were using rapid tests to confirm clinical diagnosis for Hepatitis A and Hepatitis E. To improve the diagnostic capacities and appropriate clinical management rapid diagnostic tests should be available and tests should be done routinely. Sample collection for blood and stool have since been incorporated into the Minimum Service Package required for health facilities in the camps.

AJS has been shown to be a regular public health problem in refugee settings, and in the Rohingya population in Cox’s Bazar district in particular. The characterization of the causative etiology is important to tailor appropriate preventive and responsive measures. Our results highlight the need to continue efforts to improve the long-term quality of water and sanitation in the camps, as well as for an improved detection and clinical management of Hepatitis B and C.

Supporting information

S1 Appendix. Etiologies of acute jaundice syndrome.

(PDF)

S2 Appendix. Acute jaundice syndrome case report form.

(PDF)

S3 Appendix. Acute jaundice syndrome—case definition.

(PDF)

S4 Appendix. Water quality testing results in refugee settlements from 18 September to 14 November 2017, Cox’s Bazar, Bangladesh [21].

(PDF)

S5 Appendix. Map of AJS attack rate (per 10,000 population) by age-groups reported during enhanced epidemiological surveillance strategy (between 28 February and 26 March 2018) in the Rohingya refugee camps in Cox’s Bazar, Bangladesh © 2021 by Md Khadimul Anam Mazhar is licensed under CC BY 4.0.

(TIF)

S6 Appendix. Reported AJS household transmission–definition.

(PDF)

Acknowledgments

We would like to thank the Civil Surgeon of Cox’s Bazar District of Ministry of Health and Family Welfare (MoHFW) for his full support and guidance during the outbreak response. We would also like to thank colleagues from WHO Operations Support and Logistics team for their relentless support throughout the outbreak response. We are grateful to Cox’s Bazar Medical College Hospital for their overall support, guidance and supervision in laboratory investigation. We would also like to acknowledge the Global Outbreak, Alert and Response Network (GOARN) operational support team for the assistance with deployments staff supporting from all around the globe. Special thanks to all the organizations working for Rohingya refugee response under the Health Sector for their support to this investigation. Lastly, we would like to thank the Rohingya refugees for their resilience and strength in ongoing difficult times.

Data Availability

All data used in this study are owned by a third-party stakeholder, Ministry of Health & Family Welfare (MoHFW). A written approval was obtained from the MoHFW to use this anonymised data set only for the purpose of sharing the results of this outbreak investigation and in the context of this manuscript. Any further request to access the data has to be approved by the MoHFW responsible for overseeing the Rohingya refugee response. The contact details are given below: - Civil Surgeon Office, Ministry of Health & Family Welfare, - Kolatoli Road, Cox’s Bazar, Bangladesh - Email: coxsbazar@cs.dghs.gov.bd.

Funding Statement

The authors received no specific funding for this work. The UK Public Health Rapid Support Team is funded by UK Aid from the Department of Health and Social Care and is jointly run by Public Health England and the London School of Hygiene & Tropical Medicine. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.OCHA. Rohingya refugee crisis [Internet]. Rohingya refugee crisis. 2019. p. 1–6. Available from: https://www.unocha.org/rohingya-refugee-crisis.
  • 2.Cox’s Bazar. SITUATION REPORT ROHINGYA REFUGEE CRISIS. 2020.
  • 3.ISCG. HUMANITARIAN CRISIS JRP FOR ROHINGYA.
  • 4.Feldstein LR, Bennett SD, Estivariz CF, Cooley GM, Weil L, Billah MM, et al. Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox’s Bazar, Bangladesh, 2018: A cross-sectional study. PLoS Medicine. 2020. March 31;17(3). 10.1371/journal.pmed.1003071 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wijekoon N, Babu A, Pavlin B, Hugonnet S, Tahir K El, Musto J, et al. Weekly epidemiological record Relevé épidémiologique hebdomadaire Sommaire Evaluation of the early warning, alert and response system for the Rohingya crisis, Cox’s Bazar, Bangladesh.
  • 6.Karo B, Haskew C, Khan AS, Polonsky JA, Mazhar MKA, Buddha N. World health organization early warning, alert and response system in the Rohingya crisis, Bangladesh, 2017–2018. Emerging Infectious Diseases. 2018;24(11). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Xeuatvongsa A, Pathammavong C, Phounphenhack K, Reyburn R, Feldon K, Thompson MJ, et al. Investigation of Hepatitis E Outbreak Among Refugees—Upper Nile, South Sudan, 2012–2013. Morbidity and Mortality Weekly Report. 2013;62(29):587–90. [PMC free article] [PubMed] [Google Scholar]
  • 8.Cooper BS, White LJ, Siddiqui R. Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: A modelling study. Azman AS, editor. PLOS Neglected Tropical Diseases. 2018. September 25;12(9):e0006807. 10.1371/journal.pntd.0006807 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Mellou K, Chrisostomou A, Sideroglou T, Georgakopoulou T, Kyritsi M, Hadjichristodoulou C, et al. Hepatitis a among refugees, asylum seekers and migrants living in hosting facilities, Greece, April to December 2016. Eurosurveillance. 2017. January 1;22(4). 10.2807/1560-7917.ES.2017.22.4.30448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Nakai K, Khin Maung Win, San San Oo, Arakawa Y, Abe K. Molecular characteristic-based epidemiology of hepatitis B, C, and E viruses and GB virus C/hepatitis G virus in Myanmar. Journal of Clinical Microbiology. 2001;39(4):1536–9. 10.1128/JCM.39.4.1536-1539.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Roussos A, Goritsas C, Pappas T, Spanaki M, Papadaki P, Ferti A. Prevalence of hepatitis B and C markers among refugees in Athens. World Journal of Gastroenterology. 2003. May 15;9(5):993–5. 10.3748/wjg.v9.i5.993 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mixson-Hayden T, Lee D, Ganova-Raeva L, Drobeniuc J, Stauffer WM, Teshale E, et al. Hepatitis B virus and hepatitis C virus infections in United States-bound refugees from Asia and Africa. American Journal of Tropical Medicine and Hygiene. 2014;90(6):1014–20. 10.4269/ajtmh.14-0068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.LaRocque RC, Breiman RF, Ari MD, Morey RE, Janan FA, Hayes JM, et al. Leptospirosis during dengue outbreak, Bangladesh. Emerging Infectious Diseases. 2005;11(5):766–9. 10.3201/eid1105.041212 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.UNHCR Bangladesh Operational Update, 1–29 February 2020—Bangladesh | ReliefWeb [Internet]. [cited 2021 Mar 6]. Available from: https://reliefweb.int/report/bangladesh/unhcr-bangladesh-operational-update-1-15-august-2018.
  • 15.Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Vol. 34, International Journal of Epidemiology. 2005. p. 600–9. 10.1093/ije/dyi062 [DOI] [PubMed] [Google Scholar]
  • 16.Teshale EH, Grytdal SP, Howard C, Barry V, Kamili S, Drobeniuc J, et al. Evidence of Person‐to‐Person Transmission of Hepatitis E Virus during a Large Outbreak in Northern Uganda. Clinical Infectious Diseases. 2010. April;50(7):1006–10. 10.1086/651077 [DOI] [PubMed] [Google Scholar]
  • 17.Mary E. Wilson M. Hepatitis E Epidemiology in Bangladesh. NEJM Journal Watch. 2010. September 22;2010. [Google Scholar]
  • 18.WHO. Hepatitis E [Internet]. 2019 [cited 2019 Nov 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-e.
  • 19.WHO. Hepatitis B [Internet]. [cited 2019 Dec 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
  • 20.Wasiński B, Dutkiewicz J. Leptospirosis—Current risk factors connected with human activity and the environment. Vol. 20, Annals of Agricultural and Environmental Medicine. 2013. p. 239–44. [PubMed] [Google Scholar]
  • 21.WHO. Mortality and Morbidity Weekly Bulletin (MMWB).

Decision Letter 0

Hans Tillmann

4 Dec 2020

PONE-D-20-32697

Hepatitis A outbreak among the Rohingya refugees in Cox’s Bazar, Bangladesh:  findings from enhanced epidemiological surveillance

PLOS ONE

Dear Dr. Mazhar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Hans Tillmann

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for including your ethics statement provided within your manuscript:

"The data reported were collected as public health outbreak response activities. For this 180publication, no additional primary data collection took place. However, theanalysis was done with the support of and in consultation withthe Civil Surgeon, Cox’s Bazar, Bangladesh. All individual case data was anonymized."

a. Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

b. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3. Please provide additional details regarding participant consent.

In the ethics statement in the Methods and online submission information, please ensure that you have specified (i) whether consent was informed and (ii) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. Thank you for stating the following financial disclosure:

'The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript'

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. Please include a separate caption for each figure in your manuscript.

7. Please ensure that you refer to Figure 2 in your text as, if accepted, production will need this reference to link the reader to the figure.

8. We note that Supporting Information Appendix 3 in your submission contains map images which may be copyrighted.

All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (a) present written permission from the copyright holder to publish these figure specifically under the CC BY 4.0 license, or (b) remove the figure from your submission:

a. You may seek permission from the original copyright holder of Supporting Information Appendix 3 to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish this figure under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

9. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

It is an article that describes an outbreak of viral hepatitis A associated with poor sanitary conditions in the refugee population. The presence of other etiologies, such as HBV, may be due to the fact that they already had a previous infection, considering that they are endemic areas; however, a comment could be added on the horizontal transmission of HBV in conglomerates of people. A map of the refugee location could be included.

It is important to improve bibliographic references in general. The data in the tables and graphs are repeated and could be described in the text. If it is published it could be like a short communication.

 

Major compulsory revisions

All the comments on the paper need to be addressed as follows:

<h5>1.     As the refugees migration took place in Summer of 2017 means May, June as starting point and as per epi curve the data of AJS cases showed approx.. more than 3500 cases and 6 deaths but 6 deaths were not shown and not mentioned in this articles, please include</h5>

 

<h5>2.     Location map is very important to look for clustering of cases in camps. As per Epi-curve, there is gradually increase of no. of health units under surveillance (EWARS) approx. 160 units but data had been shown to only 18 health units for 4 weeks, most probably because of more cases in Feb to March 2018 in those units, but we missed which parts of camp are more affected and we can explain better if we put map of location and camps in COX’s bazar.</h5>

 

<h5>3.     We cannot comment odd ratio without table and percentage: Naked odds ratios give no idea about the extent of this risk factor.  It’s always better to include the percent of cases and percent of controls exposed.  One could get an OR of 5 with only 20% exposed.  </h5>

 

Please send word documents more comments on track change mode.

 

Minor essential revisions

The paper could be improved by thorough editing and formatting.

      

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Peer review form peer review Dr Tripurari kumar.docx

PLoS One. 2021 Apr 29;16(4):e0250505. doi: 10.1371/journal.pone.0250505.r002

Author response to Decision Letter 0


2 Feb 2021

Response to Reviewers:

Journal Requirements:

A. When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

We thank the reviewers for drawing attention to meet PLOS One’s style requirements. We have made necessary amendments in the manuscript and file naming during our re-submission.

2. Thank you for including your ethics statement provided within your manuscript:

"The data reported were collected as public health outbreak response activities. For this 180publication, no additional primary data collection took place. However, theanalysis was done with the support of and in consultation withthe Civil Surgeon, Cox’s Bazar, Bangladesh. All individual case data was anonymized."

a. Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

b. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

We thank the reviewers for drawing attention to ethics statement. The data reported were collected as part of routine public health outbreak response activities. For this publication, no additional primary data collection took place other than the data required for outbreak response and surveillance. The formulation of this work was presented, reviewed and approved by the review committee for “Operational research during Rohingya Refugee crisis” is led by the Ministry of Health & Family Welfare (MoHFW), Bangladesh. Written approval to publish this manuscript in a journal was obtained from the Ministry of Health & Family Welfare (MoHFW), Bangladesh responsible for the oversight the response of the refugee crisis in Cox’s Bazar, Bangladesh. We have updated the ethics statement as follows as follows (lines 190 to 197):

“The data reported were collected as part of routine public health outbreak response activities. For this publication, no additional primary data collection took place other than the data required for outbreak response and surveillance. Therefore, no additional ethical approval was sought at the time of data collection. The formulation of this work was presented and discussed with the Civil Surgeon Cox’s Bazar from the Ministry of Health & Family Welfare (MoHFW) responsible for overseeing the Rohingya refugee crisis. All individual case data was anonymized.”

3. Please provide additional details regarding participant consent.

In the ethics statement in the Methods and online submission information, please ensure that you have specified (i) whether consent was informed and (ii) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

We thank the reviewers for drawing attention regarding participant consent. We have updated the text regarding participants consent (lines 155 to 158):

“Participants were provided with information about the reason for the blood tests, and how their information would be handled and stored. Verbal consent was obtained by the medical team in charge at each of the 18 participating facilities. Participants who refused to provide consent, were excluded from sample collection.”

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

We thank the reviewers for drawing attention to data availability statement. The data used to develop the manuscript related to the Rohingya refugee population living in Cox’s Bazar and are owned by Ministry of Health & Family Welfare (MoHFW). Due to the political sensitivity of the subject matter, there is restriction on sharing information on Rohingya refugee population. A written approval was obtained from the MoHFW to use this anonymised data set only for the purpose of sharing the results of this outbreak investigation and in the context of this manuscript. Any further request to access the data has to be approved by the MoHFW responsible for overseeing the Rohingya refugee response. The contact details are given below –

– Civil Surgeon Office, Ministry of Health & Family Welfare,

– Kolatoli Road, Cox’s Bazar, Bangladesh

– Email: coxsbazar@cs.dghs.gov.bd

5. Thank you for stating the following financial disclosure:

'The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript'

At this time, please address the following queries:

a. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c. If any authors received a salary from any of your funders, please state which authors and which funders.

d. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

We thank the reviewers for drawing attention to financial disclosure. We have made following changes in our manuscript (lines: 366 to 373) –

“The authors received no specific funding for this work. The UK Public Health Rapid Support Team is funded by UK Aid from the Department of Health and Social Care and is jointly run by Public Health England and the London School of Hygiene & Tropical Medicine. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

6. Please include a separate caption for each figure in your manuscript.

We thank the reviewers for drawing attention to this. We have made changes in to the manuscript accordingly.

7. Please ensure that you refer to Figure 2 in your text as, if accepted, production will need this reference to link the reader to the figure.

We thank the reviewers for drawing attention to this. We have made changes in to the manuscript accordingly (lines: 104).

8. We note that Supporting Information Appendix 3 in your submission contains map images which may be copyrighted.

All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (a) present written permission from the copyright holder to publish these figure specifically under the CC BY 4.0 license, or (b) remove the figure from your submission:

a. You may seek permission from the original copyright holder of Supporting Information Appendix 3 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish this figure under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

We thank the reviewers for drawing attention to the copyright issues regarding use of maps in the manuscript. The corresponding author is solely the copyright holder of the maps used in the manuscript. Additional copyright supporting document is also provided with the revised submission.

9. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

We thank the reviewers for drawing attention to this. We have made changes in to the manuscript. We added the segment of supporting information in the end of the manuscript (lines: 435 to 443)

B. Reviewers' comments:

It is an article that describes an outbreak of viral hepatitis A associated with poor sanitary conditions in the refugee population. The presence of other etiologies, such as HBV, may be due to the fact that they already had a previous infection, considering that they are endemic areas; however, a comment could be added on the horizontal transmission of HBV in conglomerates of people. A map of the refugee location could be included.

It is important to improve bibliographic references in general. The data in the tables and graphs are repeated and could be described in the text. If it is published it could be like a short communication.

We thank the reviewers for their valuable comments. We have added a comment on the horizontal transmission of HBV in the manuscript (line 330 to 333):

“Presence of high number of Hepatitis B in the younger age-groups indicated the need for improving immunization coverage of Hepatitis B among women of reproductive age (WRA) and among all newborns in the camps and the host community by strengthening routine immunization (4). This might in turn reduce the perinatal transmission of hepatitis viruses (18).”

We thank the reviewers for their suggestion to add a map of refugee location. We added an additional map showing the location of refugee population density in the camps titled – “Fig 1. Camp-wise distribution of the Rohingya refugee population located in Cox’s Bazar, Bangladesh” .

“ Fig 1. Camp-wise distribution of the Rohingya refugee population located in Cox’s Bazar, Bangladesh

We have also made changes according to the reviewer’s suggestion on bibliographic reference in general.

Major compulsory revisions

All the comments on the paper need to be addressed as follows:

1. As the refugees migration took place in Summer of 2017 means May, June as starting point and as per epi curve the data of AJS cases showed approx. more than 3500 cases and 6 deaths but 6 deaths were not shown and not mentioned in this article, please include

We thank the reviewers for their suggestion and added deaths in the epi curve titled – “Fig 2. Epidemiology curve of reported AJS cases against number of facilities reporting (monthly average) in EWAR system; and timing of changes to the surveillance system from daily to weekly”:

“Fig 2. Epidemiology curve of reported AJS cases against number of facilities reporting (monthly average) in EWAR system; and timing of changes to the surveillance system from daily to weekly

2. Location map is very important to look for clustering of cases in camps. As per Epi-curve, there is gradually increase of no. of health units under surveillance (EWARS) approx. 160 units but data had been shown to only 18 health units for 4 weeks, most probably because of more cases in Feb to March 2018 in those units, but we missed which parts of camp are more affected and we can explain better if we put map of location and camps in COX’s bazar.

We thank the reviewers for their suggestion, however due to resource constraints and lack of laboratory/diagnostic unit, it wasn’t possible to include all health units reporting to our surveillance network. We had to select only a handful of primary care units with diagnostic/laboratory unit (for collecting and processing blood samples).

3. We cannot comment odd ratio without table and percentage: Naked odds ratios give no idea about the extent of this risk factor. It’s always better to include the percent of cases and percent of controls exposed. One could get an OR of 5 with only 20% exposed.

We thank the reviewers for their comments and we made necessary changes in to the manuscript.

Please send word documents more comments on track change mode.

Minor essential revisions

The paper could be improved by thorough editing and formatting.

We thank the reviewers for their feedback. We have tried to improve our manuscript in our re-revised version.

Attachment

Submitted filename: Response to Reviewers (updated).docx

Decision Letter 1

Hans Tillmann

2 Mar 2021

PONE-D-20-32697R1

Hepatitis A outbreak among the Rohingya refugees in Cox’s Bazar, Bangladesh:  findings from enhanced epidemiological surveillance

PLOS ONE

Dear Dr. Mazhar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

  • sorry I missed it in the initial submission, but can you explain the fatalities/death demonstrated in figure 1, and what is the purpuse of showing death, while you do not mention death otherwise in manuscript.

  • Another good point by one reviewed, also missed in first go-around, the title may best include jaundice as starting point, and that HAV was found as dominant culprit.

  • Also, did you had an HCV IgM test available? I am not aware that such test exist.

  • I believe no one was HBV anti-HBc IgM positive?

==============================

Please submit your revised manuscript by Apr 16 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Hans Tillmann

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1 As per topic heading is concerned, “Hepatitis A outbreak among the Rohingya refugees in Cox’s Bazar, Bangladesh:findings from enhanced epidemiological surveillance”; it’s better to keep “Jaundice outbreak among the Rohingya refugees in Cox’s Bazar, Bangladesh: findings from enhanced epidemiological surveillance”- there were cases multifactorial etiologies found after investigation, so in my opinion Jaundice outbreak covers all details.

2 Regarding Hep B cases found during surveillance, warrants immunization Hep- B drive in all age group healthy individuals in 34 camps as well as zero doses to new borne ASAP to protect from spread and close monitoring to cases.

3 In last, I feel for better representation of data, descriptive data should be kept separate and analytical data should be separate.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Tripurari Kumar

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Peer review 15.02.21 Dr Tripurari kumar.pdf

PLoS One. 2021 Apr 29;16(4):e0250505. doi: 10.1371/journal.pone.0250505.r004

Author response to Decision Letter 1


3 Apr 2021

Response to Reviewers:

==============================

1. ACADEMIC EDITOR:

• sorry I missed it in the initial submission, but can you explain the fatalities/death demonstrated in figure 1, and what is the purpuse of showing death, while you do not mention death otherwise in manuscript.

- We thank the reviewer for his feedback on this. In our initial manuscript, we did not include the deaths in the epidemiological curve as deaths were reported outside our enhanced surveillance period. However, as suggested by the reviewer as added the deaths in the graph. The authors agreed to remove the deaths as suggested by the academic reviewer as it is difficult to interpret (lines 100 to 103):

Fig 1. Epidemiology curve of reported AJS cases against number of facilities reporting (monthly average) in EWAR system; and timing of changes to the surveillance system from daily to weekly

• Another good point by one reviewed, also missed in first go-around, the title may best include jaundice as starting point, and that HAV was found as dominant culprit.

- We thank reviewer for the valuable suggestion. We have changed the title of our manuscript as suggested (lines 1 to 2) –

“An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox’s Bazar, Bangladesh: findings from enhanced epidemiological surveillance.”

• Also, did you had an HCV IgM test available? I am not aware that such test exist.

- We thank the reviewer for pointing on the issue regarding HCV testing. During the epidemiological investigation, we used the “Biokit bioelisa HCV 4.0” ELISA kit, which uses anti HCV autoantibodies for detecting antigen against HCV from blood samples. The list of tests used with the name of the manufacturer is given below -

No Disease/Pathogen Diagnostic test to be performed

1 Hepatitis A Virus HAV ELISA for IgM (CTK Biotech)

2 Hepatitis B Virus Hepatitis B surface antigen (RPC Diagnostics)

3 Hepatitis C Virus Anti-HCV antibodies (Biokit bioelisa HCV 4.0)

4 Hepatitis E Virus Anti-HEV ELISA for IgM (CTK Biotech & Euroimmun)

5 Leptospirosis Leptospira lateral flow for IgM (LifeAssay)

- We made the following changes in the manuscript (lines 168 to 169) –

No Disease/Pathogen Diagnostic test to be performed

1 Hepatitis A Virus HAV ELISA for IgM

2 Hepatitis B Virus Hepatitis B surface antigen

3 Hepatitis C Virus Anti-HCV antibodies

4 Hepatitis E Virus Anti-HEV ELISA for IgM

5 Leptospirosis Leptospira lateral flow for IgM

• I believe no one was HBV anti-HBc IgM positive?

- We only used Hepatitis B surface antigen (HBsAg) testing for the detection of HBV cases.

==============================

Minor compulsory revisions:

All the comments on the paper need to be addressed as follows:

A. Result section:

1) In Table 3, Please mention which age group in first row???

N (%) Odds Ratio (95% CI) P-value

Age (in years) 275 (100%) 0.86 (0.83 to 0.89) < 0.001

This table shows two sub categories, age & gender. please make age data together and then put gender data

- We thank reviewer for his valuable suggestion. We used age (in years) as numerical variable initially and age-group as categorical variable. However, we have made following changes in the manuscript to accommodate the suggested changes and merged 2 tables together to have same format (lines 256 to 259) –

“Table 4. Association of hepatitis A seropositivity with age-group, gender, presenting symptoms and drinking water sources

OR (95% CI) P-value

Age-group

0-4 years (n=67) 1.0* -

5-9 years (n=59) 1.15 (0.40 to 3.13) 0.79

10-17 years (n=60) 0.18 (0.07 to 0.42) < 0.001

18+ years (n=89) 0.02 (0.01 to 0.06) < 0.001

Gender

Female (n=119) 1.0* -

Male (n=156) 1.32 (0.82 to 2.14) 0.256

Presenting symptoms#

Fever (n=183) 2.25 (1.35 to 3.76) 0.002

Nausea (n=155) 1.19 (0.76 to 1.93) 0.479

Abdominal pain (n=113) 0.81 (0.50 to 1.31) 0.385

Vomiting (n=70) 1.85 (1.05 to 3.27) 0.034

Fatigue (n=57) 0.83 (0.46 to 1.50) 0.542

Itching (n=38) 1.23 (0.61 to 2.47) 0.563

Joint pain (n=37) 0.42 (0.21 to 0.86) 0.018

Loss of Appetite (n=27) 3.83 (1.40 to 10.45) 0.009

Dark Urine (n=26) 3.63 (1.32 to 9.94) 0.012

Bleeding (n=7) 1.04 (0.23 to 4.74) 0.960

Convulsion (n=6) 0.38 (0.07 to 2.12) 0.271

Drinking water sources^

Tube-well (n=170) 1.27 (0.78 to 2.06) 0.342

Tap water (n=45) 1.22 (0.63 to 2.33) 0.555

Unknown sources (n=58) 0.56 (0.32 to 1.01) 0.055

*Baseline category, #Diarrhoea (n=1) and other (n=2) symptoms were omitted from the summary table, ^ water truck (n=2) was omitted from the summary table”

In Table 4, pl put the data as per no. of cases presented with symptoms like fever most common presented (n=183) followed by Nausea (n=155) and abdominal pain (n=113) and so on..

- We thank reviewer for this suggestion on data presentation. We have made the changes in the manuscript as suggested lines (256 to 259).

Map Section:

1. AR should be calculated age-wise, sex wise and location wise.

- We thank reviewer for the valuable suggestion. We have calculated the attack rates and incorporated in the manuscript (lines 205 to 215) –

“Camp-wise weekly attack rate (AR) per 10,000 population was calculated for the reported 275 AJS cases detected by the enhanced epidemiological surveillance strategy between 28 February and 26 March 2018. The weekly mean attack rate over the enhanced surveillance period (28 February to 26 March 2018) was 0.60 (95% CI: 0.28 to 0.92) per 10,000 population, across all the camps for the reported AJS cases. However, the AR varies among age-groups and was higher in younger age-groups (see Table 3). AR (per 10,000 population) for different age-groups is graphically presented in Appendix 5.

Table 3: Attack rate of reported AJS cases by age-group* and gender among all 34 camps between 28 February and 26 March 2018 in Cox’s Bazar, Bangladesh

Weekly AR/10,000 population (95% CI)

Overall 0.60 (0.28 to 0.92)

By age-group

0-4 years 0.80 (0.34 to 1.26)

5-11 years 0.73 (0.36 to 1.10)

12-17 years 0.71 (0.31 to 1.11)

18+ years 0.43 (0.15 to 0.92)

By gender

Female 0.49 (0.21 to 0.77)

Male 0.71 (0.33 to 1.09)

* Population data from UNHCR Bangladesh Operational Update, 1 - 15 August 2018, was used to calculate the AJS attack rate (14).”

2. Map of camps are shown as no. of cases with different gradients, it should be depicted as per Attack rate (No of AJS cases in camp wise/ total population of given camp %),

- We thank reviewer for the suggestion. We have created the following maps depicting attack rates in different camps (lines 100 to 103 and 454 to 457) –

Fig 1. Epidemiology curve of reported AJS cases against number of facilities reporting (monthly average) in EWAR system; and timing of changes to the surveillance system from daily to weekly

Appendix 5. Map of AJS attack rate (per 10,000 population) by age-groups reported during enhanced epidemiological surveillance strategy (between 28 February and 26 March 2018) in the Rohingya refugee camps in Cox’s Bazar, Bangladesh “

3. We can see there were 34 camps and 18 health facilities, for better interpretation, map can be merged as per catering population by each health facility and calculate AR accordingly.

- We thank the reviewer for his thoughtful suggestion. However, we do not have data on clinics’ catchment area as it is very hard to determine catchment area by facility in the camps. We used camp-wise population data to calculate attack rate per only.

Discussion Section:

1. As per topic heading is concerned, “Hepatitis A outbreak among the Rohingya refugees in Cox’s Bazar, Bangladesh:findings from enhanced epidemiological surveillance”; it’s better to keep “Jaundice outbreak among the Rohingya refugees in Cox’s Bazar, Bangladesh: findings from enhanced epidemiological surveillance”- there were cases multifactorial etiologies found after investigation, so in my opinion Jaundice outbreak covers all details.

- We thank reviewer for his suggestion. We have amended our title as follows (lines 1 to 2) –

“An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox’s Bazar, Bangladesh: findings from enhanced epidemiological surveillance.”

2. Regarding Hep B cases found during surveillance, warrants immunization Hep- B drive in all age group healthy individuals in 34 camps as well as zero doses to new borne ASAP to protect from spread and close monitoring to cases.

- We thank reviewer for this suggestion on the talking point for hepatitis B cases in the discussion section. We made the following changes as suggested by the reviewer (lines 321 to 331)–

“While Hepatitis B and C were not drivers of the AJS epidemic, the detection of significant number of infections requires attention and likely reflects high prevalence of chronic infections. l. One small study has shown significant prevalence of HBV and HCV among the Rohingya population in Bangladesh (15) and warrants further serological investigation in particular given limited capacity for clinical management within the district. Hepatitis B vaccination is part of the routine EPI programmes in the camps, and our results highlight the need to ensure adequate coverage, as well as a zero dose to new-borns to protect from spread of the infection, with close monitoring of identified cases. There is also need to maintain routine immunization programmes, to improve vaccine coverage of Hepatitis B among women of reproductive age (WRA) and under-five children both in the camps and the surrounding host community (4). This might, in turn, reduce the perinatal transmission of hepatitis viruses (19).”

3. In last, I feel for better representation of data, descriptive data should be kept separate and analytical data should be separate.

- We thank reviewer for this suggestion. We made necessary changes in the manuscript.

Please send word documents more comments on track change mode.

The paper could be improved by few editing and formatting.

- We thank reviewer for this valuable suggestion. We also tried to improve the manuscript in our revised version. We have made some changes in the discussion segment to make it more focused given all the changes.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Hans Tillmann

8 Apr 2021

An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox’s Bazar, Bangladesh:  findings from enhanced epidemiological surveillance

PONE-D-20-32697R2

Dear Dr. Mazhar,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hans Tillmann

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Hans Tillmann

16 Apr 2021

PONE-D-20-32697R2

An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox’s Bazar, Bangladesh:  findings from enhanced epidemiological surveillance.

Dear Dr. Mazhar:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hans Tillmann

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Etiologies of acute jaundice syndrome.

    (PDF)

    S2 Appendix. Acute jaundice syndrome case report form.

    (PDF)

    S3 Appendix. Acute jaundice syndrome—case definition.

    (PDF)

    S4 Appendix. Water quality testing results in refugee settlements from 18 September to 14 November 2017, Cox’s Bazar, Bangladesh [21].

    (PDF)

    S5 Appendix. Map of AJS attack rate (per 10,000 population) by age-groups reported during enhanced epidemiological surveillance strategy (between 28 February and 26 March 2018) in the Rohingya refugee camps in Cox’s Bazar, Bangladesh © 2021 by Md Khadimul Anam Mazhar is licensed under CC BY 4.0.

    (TIF)

    S6 Appendix. Reported AJS household transmission–definition.

    (PDF)

    Attachment

    Submitted filename: Peer review form peer review Dr Tripurari kumar.docx

    Attachment

    Submitted filename: Response to Reviewers (updated).docx

    Attachment

    Submitted filename: Peer review 15.02.21 Dr Tripurari kumar.pdf

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All data used in this study are owned by a third-party stakeholder, Ministry of Health & Family Welfare (MoHFW). A written approval was obtained from the MoHFW to use this anonymised data set only for the purpose of sharing the results of this outbreak investigation and in the context of this manuscript. Any further request to access the data has to be approved by the MoHFW responsible for overseeing the Rohingya refugee response. The contact details are given below: - Civil Surgeon Office, Ministry of Health & Family Welfare, - Kolatoli Road, Cox’s Bazar, Bangladesh - Email: coxsbazar@cs.dghs.gov.bd.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES